which glp-1 is safest Comparative efficacy and safety of receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials Comparing Ozempic, Wegovy and Other

Large human trials (such as the SUSTAIN and STEP programs) have not shown meaningful increases in fracture risk or significant reductions in bone mineral density directly attributable to semaglutide use

June 2024: Structure Therapeutics reported positive Phase IIa obesity data for GSBR-1290, an oral non-peptide small-molecule GLP-1 receptor agonist, achieving 6.2% placebo-adjusted mean weight loss at 12 weeks

While the results of the trial are dramatic, the fact is that before all the noise around GLP-1s, it was known that even modest weight-loss improved obesity-related conditions and that this had had no negative impact on the MedTech market, as illustrated below

139,140 It is hypothesized that DPP4 inhibitors may modulate the endocytic cascade of SARS-CoV-2 by interacting with caveolin-1, a scaffold protein required for endosome formation

Still, the MHRA makes these determinations on a case-by-case basis when complaints are received or manufacturers seek advice